share_log

Vivos Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Amman Bradford K.

SEC ·  Jun 29 08:57
Summary by Futu AI
Bradford K. Amman, the Chief Financial Officer of Vivos Therapeutics, Inc. (VVOS), has engaged in a transaction involving the company's common stock on June 20, 2024. Following the transaction, Amman directly holds a total of 80 shares of Vivos Therapeutics. The nature of the shares is direct, indicating personal ownership. The transaction details, including the number of shares transacted and the price, have not been disclosed. This financial activity is part of the regular disclosure of stock transactions by company insiders, which can be an indicator of the company's financial health and management's confidence in the business.
Bradford K. Amman, the Chief Financial Officer of Vivos Therapeutics, Inc. (VVOS), has engaged in a transaction involving the company's common stock on June 20, 2024. Following the transaction, Amman directly holds a total of 80 shares of Vivos Therapeutics. The nature of the shares is direct, indicating personal ownership. The transaction details, including the number of shares transacted and the price, have not been disclosed. This financial activity is part of the regular disclosure of stock transactions by company insiders, which can be an indicator of the company's financial health and management's confidence in the business.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.